The use of technology in diabetes in pregnancy: a position statement of expert opinion from the association of medical diabetologists (AMD), the Italian society of diabetology (SID) and the interassociative diabetes and pregnancy study group

Over the last 10 years, the number of women with diabetes during pregnancy has increased steadily. Maternal glycaemic control is the most important factor influencing maternal and neonatal outcomes, and technological advances have become integral to the evolution of diabetes care during pregnancy. However, rapid technological development must be accompanied by the equally rapid dissemination of information. In particular, knowledge of the availability of automated insulin delivery (AID) systems for managing type 1 diabetes in pregnancy, and of glucose continuous monitoring (CGM) systems for gestational and type 2 diabetes, needs to be increased. The AMD-SID Italian Diabetes and Pregnancy Study Group, supported by the Technology and Diabetes Study Group, has produced this position paper of expert opinion to review the main international guidelines and current evidence on new technologies for the management of pregnancy in women with GDM, type 1 and type 2 diabetes, and to provide detailed suggestions for the use of commercially available systems in clinical practice.